Please assess the completion status of the following clinical trial:

Trial Title: Helmet CPAP Versus HFNC in COVID-19

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: SINGLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria (all of the following):~1. Age ≥ 18 years~2. Sars-Cov-2 found in the upper or lower respiratory tract by PCR during the current disease episode~3. Peripheral oxygen saturation (SpO2) \< 92 % despite conventional low-flow oxygen therapy of at least 6 L /min for at least 15 min~4. A decision to initiate HFNC or Helmet CPAP by the attending ward physician~5. The patient has given written informed consent to participate.~Exclusion Criteria (any of the following):~1. Need for direct admission to the intensive care unit for mechanical ventilation~2. Unconsciousness or drowsiness~3. Pneumothorax~4. Carbon dioxide pressure (pCO2) \> 6 kPa in venous blood gas (VBG)~5. Underlying chronic obstructive pulmonary disease stage III-IV~6. A decision not to participate~7. Inability to comprehend the study content and give informed consent

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Helmet CPAP (Type: ACTIVE_COMPARATOR): Helmet Continuous Positive Airway Pressure (CaStar hood for CPAP therapy by Starmed/Intersurgical) driven by high-flow blender (Bio-Med Devices).
- HFNC (Type: ACTIVE_COMPARATOR): High-Flow Nasal Cannula (OptiflowTM nasal high-flow interface) driven by AIRVO 2 humidification system (Fisher and Paykel)

Based on this trial design, predict the completion outcome and termination type (if applicable).